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A trend towards increased bifidobacteria abundance was 
observed after OEP ingestion in 16S rRNA profiles, by fluo-
rescent in situ hybridization and by qPCR. Targeted LC–MS 
revealed significant increases phenolic acid concentrations 
in 24-h urine following OEP ingestion and 3,4-dihydroxy-
phenylacetic acid (DOPAC) and homovanillic acid, deriva-
tives of hydroxytyrosol, were elevated in blood. A sex effect 
was apparent in urine small phenolic acid concentrations, 
and this sex effect was mirrored by statistically significant 
differences in relative abundances of faecal bacteria between 
men and women.
Conclusion Ingestion of OEP biscuits led to a signifi-
cant increase in the metabolic output of the gut microbiota 
with an apparent sex effect possibly linked to differences in 
microbiota makeup. Increased levels of homovanillic acid 
and DOPAC, thought to be involved in reducing oxidative 
LDL cholesterol, were observed upon OEP ingestion. How-
ever, OEP did not induce statistically significant changes in 
either ox-LDL or urinary isoprostane in this study.
Keywords Olive product · Prebiotic · Polyphenols · 
Metabolomic · Tyrosol glucoside · Tyrosol group
Introduction
Olives and olive oil are important and characteristic com-
ponents of the Mediterranean diet, a dietary pattern shown 
to improve on both physical and mental quality of life, and 
reduce the risk of chronic diet-associated disease, especially 
cardiovascular disease (CVD) [1]. Indeed, extra-virgin 
olive oil, as part of a Mediterranean style diet significantly 
reduced both the incidence of composite CVD end points 
and total mortality in the PREDIMED study [2]. Polyphe-
nols, complex aromatic plant secondary metabolites, are 
Abstract 
Purpose Olive pomace is a major waste product of olive 
oil production but remains rich in polyphenols and fibres. 
We measured the potential of an olive pomace-enriched bis-
cuit formulation delivering 17.1 ± 4.01 mg/100 g of hydrox-
ytyrosol and its derivatives, to modulate the composition and 
metabolic activity of the human gut microbiota.
Methods In a double-blind, controlled parallel dietary 
intervention 62 otherwise healthy hypercholesterolemic 
(total plasma cholesterol 180–240 mg/dl) subjects were 
randomly assigned to eat 90 g of olive pomace-enriched 
biscuit (olive-enriched product, OEP) or an isoenergetic con-
trol (CTRL) for 8 weeks. Fasted blood samples, 24-h urine 
and faecal samples were collected before and after dietary 
intervention for measurement of microbiota, metabolites and 
clinical parameters.
Results Consumption of OEP biscuits did not impact on 
the diversity of the faecal microbiota and there was no sta-
tistically significant effect on CVD markers. A trend towards 
reduced oxidized LDL cholesterol following OEP ingestion 
was observed. At the genus level lactobacilli and Rumino‑
coccus were reduced in OEP compared to CTRL biscuits. 
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independently linked to these health effects [1, 3]. Olives 
and various olive oils and extracts have been shown to 
mediate different health effects in humans, many associated 
with CVD risk. Olive extracts have been reported to lower 
systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) from baseline in both hypertensive and pre-hyperten-
sive individuals [4–7] and to improve plasma lipid profiles in 
both normo-lipidaemic and hypercholesterolaemic subjects 
[4, 6, 8–10]. Olive extracts have also been found to induce 
acute reductions in arterial stiffness [11], which agrees with 
data suggesting that olive oil and olive extract significantly 
improve vascular function [12, 13] and blood pressure [14]. 
Currently, these improvements are thought to be associated 
with polyphenol-rich olive oil fractions rather than other 
bioactives which may be present [15, 16]. In contrast, other 
studies have failed to demonstrate significant modulation of 
CVD biomarkers upon olive extract ingestion. For example, 
olive leaf extracts did not appear to improve plasma lipids 
[7, 17], ambulatory blood pressure, cytokines and/or carotid 
intima-media thickness [17] in different studies. However, 
the European Food Safety Authority (EFSA) has recognized 
a specific health claim for the polyphenol extract of olive 
for protection of LDL cholesterol particles against oxidative 
damage—although they also noted that there is a lack of 
evidence for other health claims including maintenance of 
normal blood pressure and HDL cholesterol levels, reduced 
inflammation and improved gastrointestinal function [18]. 
EFSA considers that the claim that “consumption of olive 
oil polyphenols contributes to the protection of blood lipids 
from oxidative damage” reflects the scientific evidence, and 
that a dose of 5 mg of hydroxytyrosol and its derivatives 
(e.g. oleuropein complex and tyrosol) in olive oil should be 
consumed daily for food products to bear the health claim. 
In olive, the majority of polyphenols present belong to the 
tyrosol group [hydroxytyrosol (HT), tyrosol (TYR) and 
conjugated forms like oleuropein]. These conjugated forms 
are extensively hydrolyzed in the stomach [19] to HT and 
TRY, which are either absorbed in the small intestine and 
undergo extensive phase I and II biotransformation or reach 
the colon where they undergo biotransformation by the resi-
dent microbiota [19, 20]. The most common derivatives are 
small phenolic acids like homovanillic acid (HVA), dihy-
droxyphenylacetic acids (DHPAA), hydroxyphenylacetic 
acid (HPAA), protocatechuic acid and benzoic acids for 
example. The impact of olives or their constituent parts on 
the composition and metabolic activity of the human intes-
tinal microbiota is, however, poorly understood. One recent 
study has shown that thyme phenolic compounds at differ-
ent doses in olive oil can induce a small increase in bifido-
bacteria using the quantitative culture-independent method 
fluorescent in situ hybridization (FISH), with the suggestion 
that this change in microbiota could be related to improved 
LDL cholesterol oxidative status [21]. Similarly, a sex effect 
in terms of metabolism of HT and related compounds has 
been observed in rats with the suggestion that differential 
excretion of HT derivatives between male and female ani-
mals might be due to sex-linked differences in enterohepatic 
circulation [22]. However, no data are reported for differ-
ences in metabolism of these compounds between men and 
women or indeed, whether such differences if they do exist, 
could be due to sex-specific differences in gut microbiota. 
To date, no studies have reported whether olives or olive 
pomace can impact on the relative abundances of the human 
gut microbiota, on the diversity of the gut microbiota and 
only a few studies have specifically addressed the metabolic 
end products produced by combined host–microbiota co-
metabolism of olive polyphenols [20, 21].
Olives contain many potential biologically active com-
pounds such as polyphenols, dietary fibre (including pectin), 
oleic acid, linoleic acid and other beneficial fats, tocophe-
rols, phytosterols and squalene. Olive oil is extracted from 
the fruit of Olea europaea, leaving waste in the form of 
olive water and solid olive pomace. The olive pomace and 
wastewater produced from oil extraction processes contain 
macromolecules such as polysaccharides, lipids, proteins 
and polyphenolic compounds (mainly of the tyrosol group) 
which can range from 1 to 8 g/l [23] in wastewater and 2.9 
to 3.7 mg/l in olive pomace [24]. The annual worldwide pro-
duction of olive oil is about 2 million metric tons reported 
for 2015/16 (average: COI, 2017). For each ton of olive oil 
the waste produced is dependent on the fruit quality, ripeness 
and extraction technology and typically ranges from 2.75 to 
4 tons of olive pomace and 1–8 m3 of wastewater [25–27]. In 
addition these olive mill wastes are produced in significantly 
large quantities during the short olive production season and 
because the waste cannot be disposed of through ordinary 
waste treatment systems, disposal of wastewater and olive 
pomace is a major environmental problem and cost to the 
industry. Given the push towards a green economy, there is 
a stimulus for the oil industry to move towards a circular 
economic model, reducing waste production or adding value 
to waste streams, developing added value secondary prod-
uct lines. To this end, we have developed an olive pomace 
extract as a functional food ingredient. This olive pomace, 
which delivers 17.1 ± 4.01 mg/100 g HT and its derivatives, 
is also rich in fibres and our preliminary in vitro data showed 
it was fermentable and leads to increased numbers of bifi-
dobacteria in pH-controlled faecal batch cultures (data not 
shown). For this current study, we have incorporated this 
olive pomace into a biscuit formulation. For flavour, texture 
and constitutional reasons, other ingredients were also nec-
essary including extra virgin olive oil and flours from chest-
nut, pea and buckwheat, but the olive pomace remained the 
dominant ingredient and the dominant source of polyphenols 
(> 90% of polyphenols present in the final biscuit). Here we 
report the effect of this olive pomace-enriched biscuit on 
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the human gut microbiota, their metabolic output and on 
various biomarkers of CVD and inflammation. The study 
was conducted jointly by researchers at Fondazione Edmund 
Mach (San Michele all’Adige, Italy), OlioCru s.r.l (Arco, 
Italy) and the study centre was the Casa di Cura Eremo di 




The study was a double-blind, randomized, controlled, paral-
lel trial (Italy protocol Prebioil2 number: 6/2015, Clinicaltri-
als.gov ID: NCT02664428, see Fig. 1 for the study design). 
This study was conducted according to the guidelines laid 
down in the Declaration of Helsinki, and all procedures 
involving human subjects were approved by the Ethic Com-
mittee for Clinical Trials of the Trento Azienda Provinciale 
Servizi Sanitari (APSS). The clinical trial was carried out at 
the Casa di Cura Eremo di Arco (Arco, TN, Italy) between 
November 2015 and June 2016. The primary outcome meas-
ure was the faecal microbiota analysis by Illumina sequenc-
ing and fluorescence in situ hybridization (FISH) carried 
out with probe for Bifidobacterium spp., Lactobacillus spp. 
and Ruminococcus spp. The secondary outcome measures 
were related to cholesterol analysis in plasma [total, LDL, 
HDL cholesterol, oxidized LDL, triglycerides, apolipopro-
teins A–I and B (APO A and APO B)] together with the 
analysis of the variation of polyphenols and their metabolites 
in plasma and urine. Additional measures were the analyses 
of the anthropometric indices, the fasting plasma insulin, 
glucose and C-reactive protein (CRP) and the analysis of iso-
prostane F2 in urine. This study was powered for changes in 
blood LDL cholesterol and changes in faecal bifidobacteria. 
Since previous studies have shown that fewer individuals are 
required for measuring changes in faecal bifidobacteria and 
because of its clinical significance, the sample size calcula-
tion was performed only for changes in LDL cholesterol lev-
els. Based on measures from a previous parallel trial design 
using similar products [28], we assessed as clinical signifi-
cant end point the average LDL decrease of 15.44 mg/dl 
with a standard deviation of 14.28 mg/dl. According to Sne-
decor and Cochran equation with significance value α equal 
to 0.05 and a 90% power (1 − β) [29], the minimum number 
of subjects to enrol was 28. Taking into account possible 
dropouts, a total of 73 subjects were enrolled and randomly 
assigned to the dietary intervention with the product under 
investigation (OEP) or to the control dietary intervention.
Intervention foods
The study product “PreBiÒ®”, herein called olive pomace-
enriched product (OEP), was a bakery product comprising 
dehydrated food-grade olive powder, together with chest-
nut, peas, buckweat flour, extra virgin olive oil (EVOO), 
salt and sugar according to the OlioCRU proprietary recipe, 
and the OlioCRU pending Patent Process. The product was 
prepared at a local bakery. The product contained about 
411 ± 25 mg/100 g of total biophenols measured according 
to the COI method of which 17.1 ± 4.01 mg/100 g belong to 
the tyrosol group polyphenols and were measured according 
to Gasperotti et al. [30].
The product corresponded to the energy intake of 
434 Kcal/100 g (average of three replicates).
Subjects were provided with single 90 g daily doses 
and instructed to consume one each day of the 8 weeks of 
intervention. The control product comprised wheat flour, 
sugar, salt and low-polyphenol EVOO, food colourings in 
safety-approved quantities to match the test product OEP as 
closely as possible in appearance, taste, texture. The product 
contains less than 1 mg/100 g of total biophenols measured 
according to the IOC official method (IOC 2009) of which 
0.7 ± 0.5 mg/100 g belong to the tyrosol group. The product 
Fig. 1  Schematic representation of study design. *At the end of the 
study because of antibiotic usage or non-compliance for consump-
tion of the product, two people were excluded from the olive-enriched 
product (OEP) group and one from the control group
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corresponds to an energy intake of 419 Kcal/100 g (average 
of three replicates). Table 1 shows the gross nutritional com-
position of the OEP and control (CTRL) biscuits.
Recruiting
Healthy volunteer were recruited through advertisement 
in the geographical area of Arco (TN) in the northeast of 
Italy. Advertisement was carried out via flyer, posters and 
e-mails. Individuals who answered the call were asked their 
weight and height and those who corresponded to BMI in 
the range established by the inclusion criteria were given an 
appointment for the general health assessment to determine 
conformity with other inclusion/exclusion criteria. At the 
clinic a health and lifestyle questionnaire was completed, 
eco-cardiogram and physical examinations were performed 
together with collection of urine and fasted blood samples. 
The inclusion criteria were non-smoking status, age between 
30 and 65 years, BMI between 20 and 29.9 kg/m2, plasmatic 
total cholesterol between 180 and 240 mg/dl, being free from 
chronic disease, including cardiovascular disease, diabetes, 
cancer, inflammatory or digestive disorders. Pregnancy or 
breastfeeding, and individuals consuming more than 21 U/
week of alcohol were excluded. Subjects were excluded if 
taking statins or other medication or dietary supplements 
that may affect lipids. Uncontrolled hypertension was an 
exclusion criteria, and to be included the subjects were either 
not hypertensive or under hypertensive medication and pre-
senting with average SBP below 121 mmHg and average 
DBP 90 mmHg. Subjects with food allergies or intolerances 
were also excluded.
Randomisation and blinding
Treatment allocation was done using a random block design. 
A six-digit code was assigned to each recruited individual. 
The products was randomly assigned to the subject code by 
an external individual by picking codes form a bag in a blind 
manner but matching groups by age and sex. Each daily dose 
was prepared in a food-grade sealed box enveloped in dark 
green paper sachet. The treatment codes were kept offsite 
and not released until statistical analysis was complete. 
Therefore, allocation concealment was achieved and both 
researchers and subjects were blinded to which product was 
being consumed at which time.
Screening
Clinical visits took place at the beginning of week 1, and 
at the end of week 8 at the Casa di Cura Eremo di Arco 
s.r.l., Via XXI Aprile 1, 38062 Arco (TN) Italy. Subjects 
arrived for screening fasted and measurements of height and 
weight were taken in a Kern scale (Kern & Sohn, Balingen, 
Germany) with stand and height rod (Mod MPB300K100P) 
to calculate BMI. Blood pressure was measured after 5-min 
rest, seated and with the subject’s dominant arm resting on 
a table, using an Omron digital blood pressure equipment 
(HEM-705 CP).
Three readings were taken 60 s apart and averaged. Sub-
jects were not permitted to talk during measurements. Blood 
pressure was measured at the screening visit (T-1) and later 
at the beginning (T0) and at the end of the treatment (T1). 
Blood samples obtained via single venepuncture were col-
lected into heparin and EDTA vacutainers (BD) and used 
for the analysis established for health. A total of 73 suitable 
subjects were identified and accepted onto the trial.
Each subject was informed about the study aims and pro-
cedure to allow them to sign and informed consent. Eligible 
participants were asked to provide written informed consent 
to take part in the study.
Compliance measures
Subjects were asked to return all remaining full or empty 
daily packages of test product after 8 week intervention. 
Remaining material were weighed and recorded. Subjects 
were asked to complete weekly online questionnaires and 
supplied with daily tick sheets.
Faecal sample collection
Volunteers were provided with a sealable pot, and sterile bag 
to collect the stool sample, each of them were instructed to 
collect the stool sample in the sterile bag, put it into the pot 
and, prior to sealing the pot, to add an atmosphere genera-
tion system AnaeroGen Compact (Thermo Scinetific). This 
ensured an anaerobic environment during sample transport. 
Samples were collected and treated for further analysis or 
stored at − 80 °C within 24 h.
Urine sample collection
Volunteers were supplied 3-l sterile containers to collect the 
24-h urine samples. Each container was added with 15 ml of 
3M hydrochloridric acids as a preservative. After collection, 
the total urine volume was measured and the samples for 
further analysis were prepared and stored at − 80 °C.
Biochemical measures
Blood collected in EDTA and heparin vacutainers was cen-
trifuged at 1550×g for 15 min to separate plasma. Plasma 
was immediately analysed or stored in low-binding Eppen-
dorf tubes (Axygen, Tewksbury MA, USA) at − 80 °C until 
analysis. Total cholesterol (TC), HDL cholesterol (HDL), 
LDL cholesterol (LDL), apolipoprotein A1 (Apo A1) and B 
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Table 1  Food supplements’ nutritional value (g/100 g, mean ± standard deviation) (a) and polyphenol composition (μg/g) (b)
OPE (g/100 g) Ctrl (g/100 g)
A
 Carbohydrates 49.2 (± 1.04) 70.9 (± 2.19)
 Lipids 18.5 (± 0.40) 8.1 (± 2.40)
 Proteins 16.1 (± 4.39) 10.9 (± 0.92)
 Dietary fibre 13.3 (± 0.17) 3.4 (± 0.35)
 Salt 0.7 (± 0.2) 0.7 (± 0.2)
Compound OEP Ctrl
Mean SD Mean SD
B
 Cinnamic acid 0.39 0.04 < 0.005 –
 Vanillin 0.26 0.02 < 0.01 –
 Esculin 0.14 0.01 < 0.005 –
 Neochlorogenic acid 0.40 0.18 < 0.01 –
 Chlorogenic acid 55.08 4.24 < 0.025 –
 Fertaric acid 0.09 0.02 < 0.01 –
 t-Coutaric acid 0.68 0.13 < 0.01 –
 Apigenin 3.30 0.13 < 0.0025 –
 Luteolin 10.14 3.40 1.19 1.26
 Luteolin-7-O-Glc 8.95 0.88 < 0.0025 –
 Apigenin-7-Glc 1.23 0.07 < 0.0025 –
 Naringenin 0.17 0.03 < 0.0025 –
 Epicatechin 0.48 0.36 < 0.1 –
 Kaempferol 3.44 0.52 < 0.0025 –
 Quercetin 2.57 0.26 < 0.0025 –
 Quercetin-3-Rha 1.52 0.11 < 0.005 –
 Kaempferol-3-Glc 2.25 0.39 < 0.0025 –
 Syringetin-3-Glc + syringetin-3-Gal (as syr-
3-glc)
0.14 0.02 < 0.0025 –
 Kaempferol-3-rutinoside 0.07 0.02 < 0.0025 –
 Arbutin 0.21 0.05 0.31 0.11
 4-Hydroxybenzoic acid 1.02 0.33 0.81 0.12
 p-Coumaric acid 1.01 0.38 0.71 0.09
 Vanillic acid 2.98 0.43 1.37 0.18
 Caffeic acid 1.19 0.11 < 0.025 –
 Isoferulic acid 0.74 0.03 1.04 0.18
 t-Ferulic acid 21.21 0.03 33.65 4.75
 Ellagic acid 6.40 1.26 < 0.025 –
 Pyrocatechol 7.20 0.60 9.09 2.36
 Protocatechuic acid 4.69 0.65 < 0.025 –
 Scopoletin 0.26 0.08 < 0.0025 –
 Cryptochlorogenic acid 3.65 0.64 < 0.025 –
 Quercetin-3-Glc + quercetin-3-gal(as que-3-
glc)
0.60 0.37 < 0.005 –
 Rutin 2.32 0.42 < 0.0025 –
 Hydroxytyrosol 8.11 4.41 0.79 0.32
 Chrysoeriol 0.13 0.02 0.07 0.02
 Salidroside 121.19 34.59 < 0.25 –
 Pinoresinol 1.11 0.15 < 0.0025 –
 Oleuropein 5.72 0.78 < 0.005 –
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(Apo B) triglycerides (TG), CRP, glucose (GLU) and insulin 
(Ins) were measured at Clinic Casa di Cura Eremo Labora-
tory (Arco, TN, Italy), using ILab 650 chemistry analyser 
(Instrumentation Laboratories UK Ltd, Warrington, United 
Kingdom) for all measures except insulin which was meas-
ured using a Roche COBAS 6000.
Oxidized LDL was measured in duplicate via an ELISA 
kit (Mercodia, Sweden).
F2 isoprostane urinary total (conjugated and non-con-
jugated) were measured using the enzyme immunoassay 
based kit Urinary Isoprostane Elisa Kit (Oxford Biomedi-
cal Research, USA).
Metagenomic analysis
A whole fresh stool sample was collected at T0 and T1. 
The stool was stored at − 80 °C. DNA was extracted from 
100 mg stool aliquots using Power faecal DNA extraction 
kit (MOBio), following the manufacturer’s instructions. 
Metagenomic sequencing was performed to evaluate micro-
biota diversity and genus-level abundances. Using the spe-
cific bacterial primer set 341F (5′ CCT ACG GGNGGCW-
GCAG 3′) and 806R (5′GAC TAC NVGGGTWTCT AAT CC 
3′) with overhang Illumina adapters, total genomic DNA was 
subjected to PCR amplification by targeting a ~ 460-bp frag-
ment of the 16S rRNA variable region V3–V4. PCR amplifi-
cation of each sample was carried out using 25-μl reactions 
with 1 μM of each primer. Specifically 12.5 μl of 2× KAPA 
HiFi HotStart ReadyMix, 5 μl forward primer, 5 μl reverse 
primer were used in combination with 2.5 μl of template 
DNA (5 ng/μl). All PCR amplifications were carried out 
using a GeneAmp PCR System 9700 (Thermo Fisher Sci-
entific) and the following steps—melting step; 94 °C for 
5 min (one cycle), annealing step; 95 °C for 30 s, 55 °C for 
30 s, 72 °C for 30 s (30 cycles), extension step; 72 °C for 
5 min (1 cycle). The PCR products were checked on 1.5% 
agarose gel and cleaned from free primers and primer dimer 
using the Agencourt AMPure XP system (Beckman Coulter, 
Brea, CA, USA) following the manufacturer’s instructions. 
Subsequently dual indices and Illumina sequencing adapters 
Nextera XT Index Primer (Illumina) were attached by seven-
cycle PCR (16S Metagenomic Sequencing Library Prepara-
tion, Illumina). The final libraries, after purification by the 
Agencourt AMPure XP system (Beckman), were analysed 
on a Typestation 2200 platform (Agilent Technologies, 
Santa Clara, CA, USA) and quantified using the Quant-IT 
PicoGreen dsDNA assay kit (Thermo Fisher Scientific) by 
the Synergy 2 microplate reader (Biotek). Finally all the 
libraries were pooled in an equimolar way in a final ampli-
con library and analysed on a Typestation 2200 platform 
(Agilent Technologies, Santa Clara, CA, USA). Bar-coded 
library were sequenced on an Illumina® MiSeq (PE300) 
platform (MiSeq Control Software 2.0.5 and Real-Time 
Analysis software 1.16.18). Differences in relative abun-
dance after intervention (V2–V1) with treatment W or P 
were analysed using non-parametric t test (Mann–Whitney 
U test).
Quantitative microbial molecular techniques
Flow cytometry (FCM) fluorescent in situ hybridization 
(FISH)
1:10 dilution (wt:vol) of the faecal sample was prepared by 
weighting out 2–3 g of faecal sample and diluting it with 
1M PBS on the scale (e.g. 3 g of sample + 27 g of PBS, 
considering that 1 ml of 1M PBS weights 1 g). The diluted 
sample was homogenized using a Stomacher 400 (Seward) 
at the speed of 230 rpm for 2 min or until it appeared homo-
geneous. Ten millilitre of the suspension was transferred 
into a 15-ml falcon tube containing glass beads; the tube 
was mixed by vortexing for about 30 s, then centrifuged at 
1100 rpm for 2 min to pellet fibrous particles. Then 375 μl 
of the suspension were transferred into a 1.5-ml Eppendorf 
tube containing 1125 μl of 4% paraformaldehyde (PFA). 
The suspension was fixed in 4% PFA for 4–24 h at 4 °C. 
After fixation the tubes were centrifuged at 13,000 rpm 
for 5 min and the pellet were resuspended in 1 ml of filter-
sterilized 1M PBS. This washing procedure was repeated 
twice, then the tubes were centrifuged again at 13,000 rpm 
for 5 min, supernatant was carefully removed and the pel-
let was finally resuspended in 150 μl of filter-sterilized 1M 
PBS. One hundred and fifty (150) microlitre of absolute 
ethanol was added and the samples were mixed by inver-
sion and immediately stored at − 20 °C. For FCM-FISH 
analysis, 10 μl of the fixed faecal sample was resuspended 
in 190 μl of PBS 1X sterile. Every step was done in 96-well 
plates. After resuspending, the sample was centrifuged at 
Values below the limit of quantification are not shown
Table 1  (continued)
Compound OEP Ctrl
Mean SD Mean SD
 Diosmetin 0.13 0.03 0.06 0.01
 Tyrosol 8.86 0.86 6.31 0.72
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4000 rpm for 15 min. The sample was resuspended in 200 μl 
of Tris–EDTA buffer and then centrifuged another time at 
4000 rpm for 15 min. For hybridisation with the probes spe-
cific for Lactobacillus/Enterococcus spp. [31], Bifidobac‑
terium spp. [32] and Ruminococcus spp. [33] that needed 
lysozyme treatment to render the cell wall more perme-
able to the probes, we resuspended the sample in 200 μl of 
Tris–EDTA containing 1 mg/ml of lysozyme and incubated 
for 10 min at room temperature. After that period, sample 
was washed with centrifugation and resuspended in 50 μl 
of hybridization buffer [0.9 M NaCl, 20 mM Tris–HCl (pH 
7.5), 0.1% [wt/vol] sodium dodecyl sulphate (SDS)] with 
5 μl of 50 ng/μl fluorescently Cy5-labelled oligonucleotide 
probe and incubated at the appropriate hybridization temper-
ature (Table 2). Washing was repeated and the sample was 
resuspended in 200 μl of hybridization buffer without SDS 
and incubated at the appropriate wash temperature (Table 2). 
After washing, sample was resuspended in SYBR Green, 
used to enumerate the total cells. SYBR Green binds to DNA 
and the resulting complex absorbs blue light (λmax = 497 nm) 
and emits green light (λmax = 520 nm). A blank sample (with-
out the fluorescently Cy5-labelled oligonucleotide probe and 
without the SYBR Green) was prepared and for every sam-
ple, following the same steps as per the hybridized sample, 
to set the threshold of the gates of the flow cytometer that 
permits the revelation of the microbial species and exclude 
the false positives due to the potential autofluorescence of 
the sample. FCM was performed using Guava easyCyte™ 
Single Sample Flow Cytometer (Millipore) with a single 
blue (488 nm), dual blue and red (642 nm), or triple blue, 
red, and violet (405 nm) excitation lasers that provided 12 
simultaneous detection parameters, including 10 fluorescent 
colours plus forward and side scatter for size and granu-
larity determination. The FCM parameters were adjusted 
to give particle counts of 1000 events in total. Data were 
analysed by the InCyte software, version 4.1.1. To avoid 
loss of the signal intensity of hybridized cells, the samples 
were kept in the dark until the FCM analysis. Results were 
expressed as the percentage of cells hybridized with the 
group-specific-Cy5 probe calculated on the total bacteria, 
counted after SYBR Green staining. Also absolute numbers 
were obtained.
Quantitative PCR
DNA extraction was performed using the FastDNA™ SPIN 
Kit for Feces (MP Biomedicals). Amplifications were per-
formed with sets of primers specific for Bifidobacterium 
Table 2  Anthropometric and 
clinical parameters, mean 
(± standard deviation), before 
(T0) and after (T1) dietary 
intervention with olive-enriched 
product (OEP) or control (Ctrl)
p value is relative to one-way ANOVA on the difference between T0 and T1
SYS systolic pressure, DIA diastolic pressure, WM waist measure, HM hips measure, BMI body mass index, 
TC plasma total cholesterol, HDL plasma high-density lipoproteins, LDL plasma low-density lipoproteins, 
TG plasma triglycerides, Apo Apolipoproteins in plasma, Glu plasma glucose, Ins plasma insulin, CRP 
plasma reactive C protein, oxLDL plasma oxidized LDL, F2 Isp total 24-h urine Isoprostane F2
Dietary supplement Dietary supplement ANOVA
p value
OEP Ctrl
T0 T1 T0 T1
SYS (mmHg) 120 (± 11.4) 122 (± 12.4) 122 (± 15.0) 121 (± 17.2) 0.416
DIA (mmHg) 78 (± 7.4) 78 (± 7.7) 78 (± 9.7) 77 (± 9.8) 0.586
WM (cm) 84 (± 11.9) 84 (± 11.) 83 (± 11.7) 82 (± 10.9) 0.931
HM (cm) 102 (± 6.4) 102 (± 6.3) 102 (± 5.5) 102 (± 5.9) 0.944
Weight (kg) 70 (± 12.1) 70 (± 12.1) 71 (± 11.6) 70 (± 11.6) 0.974
BMI (kg/m2) 24 (± 3.4) 24 (± 3.5) 24 (± 3.0) 24 (± 3.0) 0.956
TC (mg/dl) 204 (± 22.0) 202 (± 20.7) 217 (± 22.0) 213 (± 26.9) 0271
HDL (mg/dl) 64 (± 11.7) 64 (± 11.5) 66 (± 14.0) 65 (± 12.8) 0.395
TC/HDL 3.3 (± 0.7) 3.2 (± 0.7) 3.5 (± 0.8) 3.4 (± 0.9) 0.592
LDL (mg/dl) 120 (± 18.6) 118 (± 20.4) 129 (± 21.7) 126 (± 24.7) 0.378
TG (mg/dl) 92 (± 32.9) 94 (± 36.1) 96 (± 51.3) 95 (± 49.0) 0.924
Apo A1 (mg/dl) 144 (± 15.9) 145 (± 16.5) 145 (± 21.3) 144 (± 17.0) 0.636
Apo B (mg/dl) 91 (± 13.8) 91 (± 15.3) 95 (± 14.6) 95 (± 17.7) 0.920
Glu (mg/dl) 93 (± 7.0) 93 (± 6.9) 93 (± 10.9) 95 (± 10.8) 0.418
Ins (mcU/ml) 7.0 (± 5.3) 6.1 (± 2.8) 6.7 (± 5.1) 6.5 (± 5.0) 0.500
CRP (mg/L) 1.5 (± 2.7) 1.4 (± 2.2) 1.1 (± 1.0) 1.2 (± 1.3) 0.964
Ox LDL (U/L) 59.8 (± 16.7) 57.3 (± 17.2) 63.5 (± 17.2) 64.3 (± 21.3) 0.634
F2 Iso (μg/24 h) 2.20 (± 0.90) 2.22 (± 0.84) 2.04 (± 0.68) 2.01 (± 0.94) 0.739
70 Eur J Nutr (2019) 58:63–81
1 3
spp. [Bif F: TCG CGT C(C/T)G GTG TGA AAG; Bif R: 
CCA CAT CCA GC(A/G) TCC AC] and for total bacteria 
(Bact 1369: CGG TGA ATA CGT TCC CGG; Prok 1492 
TAC GGC TAC CTT GTT ACG ACTT). Reactions were 
performed at the specified conditions (see reference) using 
SsoFAST Evagreen SupemixKit (BIO RAD) and a Light-
cycler 480 PCR machine (Roche). Quantifications were 
done using standard curves obtained by amplifying pure 
cultures of Bb12 which had been previously quantified by 
plate counting. For total bacteria a mixture of bacterial DNA 
was obtained by pooling the total faecal genomic DNA from 
four faecal samples, which had been previously enumerated 
using FCM-FISH.
Metabolite analysis
Targeted metabolomics analysis by UHPLC–ESI-MS/MS 
was carried out as previously described [30, 34] on 24-h 
urine and fasted blood samples. After methanol extraction 
of polyphenols, analysis was performed by an ultra-perfor-
mance liquid chromatographic system (UHPLC) coupled 
with a tandem mass spectrometer. The system used was an 
ACQUITY UPLC system coupled to a Xevo TQ triple quad-
rupole via an electrospray (ESI) interface (Waters, Milford, 
MA, USA). The separation was performed with a Waters 
ACQUITY UPLC column HSS T3 (100 mm × 2.1 mm, 
1.8 μm) equipped with a guard column. The injection vol-
ume was 5 μl. Mobile phases of 0.1% formic acid in Milli-
Q water (A) and 0.1% formic acid in acetonitrile (B) were 
used. Chromatographic separation was performer using 
a gradient as follows: 0 min, 5% B; 0–3 min, 5–20% B; 
3–4.30 min, 20% B; 4.30–9 min, 20–45% B; 9–11 min, 
45–100% B; 11–14 min, 100% B; and 14.01–17 min, 5% 
B as equilibration time. For calibration, a standard mixture 
of polyphenol metabolites was serially diluted in aqueous 
methanol (50:50) at a concentration range of 0.01–20 mg/l. 
Quantitative data were processed withTargetlynx software 
(Masslynx, Waters).
Statistical analysis
Statistical analysis was performed using STATISTICA 13.1 
statistics software for data analysis. Data were checked 
for normality using the Kolmogorov–Smirnov and Shap-
iro–Wilk tests. Treatment effects were assessed using one-
way analysis of variance, or non-parametric Mann–Whitney 
test. Treatments were compared to each other using a paired 
Student’s t test. p values < 0.05 were deemed statistically 
significant. qPCR data analysis was performed using facto-
rial ANOVA (factors: treatment, time) with FDR correction. 
Urine and plasma metabolite data analysis was performed 




A total of 73 suitable subjects were identified and were 
accepted onto the trial to begin the dietary intervention. 
Eight did not finish the study. Two subjects dropped out 
because of illness not related to the intervention (flue and 
surgery), one for family-related issues, five did not like the 
taste of the product and dropped out. Exclusion occurred 
because of deviation from the protocol: one volunteer 
declared after finishing the study to have taken antibiot-
ics and two subjects were excluded because they did not 
consume the product as directed (more than 25% returned 
unconsumed). In total 62 people completed the study suc-
cessfully and were included in the statistical analysis. In 
detail, 32 females and 30 males, between 30 and 65 years 
old, with BMI from 20 to 29.9 (average 24 ± 3.4) and total 
cholesterol ranging between 180 and 240 mg/dl completed 
the study. Female group had an average age of 48 years 
(± 8.5), while the male group average age was 49 (± 9.6). 
Between the treatment groups at baseline, blood pressure 
(average 120/74 and 122/74), BMI (average 24 and 24) and 
total cholesterol (average 204 and 217), no significant dif-
ferences were measured (Table 2).
Faecal microbiota analysis
16S rRNA gene community analysis
A total of 8,924,305 reads was generated, with an average 
of 68,648.5 ± 36,038.2, mean ± SD, high-quality 16S rRNA 
gene sequences per stool sample. Microbiota diversity was 
evaluated for alpha diversity (diversity within a sample, 
Chao index) and beta diversity (diversity between samples, 
Bray–Curtis dissimilarity) using QIIME (https://www.qiime.
org, [35]). Sequences with expected error rate > 1.5% and 
length < 400 bp were removed from analysis. After filtering 
and chimera removal, 1418.2 ± 623.9, mean ± SD, Opera-
tional Taxonomic Units (OTU) were obtained on average per 
sample analysed. OTUs that were present in less than 25% 
of the samples were removed.
The two intervention treatments did not show statistically 
significant differences in alpha diversity (2634.54 ± 943.69 
vs 2682.012 ± 1177.8 and 2419.24 ± 1170.06 vs 
2753.09 ± 875.9 Chao index, V1 vs V2, OEP and CTRL, 
respectively; p = 0.29) and beta diversity (0.433 ± 0.087 vs 
0.43 ± 0.064 Bray–Curtis dissimilarity index, mean ± SD, 
OEP vs CTRL, respectively; p = 0.66) (Fig. 2a, b).
At the phylum level, although there was a trend towards 
increased Actinobacteria with both treatments, there was no 
statistically significant change within or between treatments 
over the course of the trial (Fig. 3).
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At a genus taxonomic level, a significant although very 
small increase of Lactobacillus and Ruminococcus was 
observed after intervention with CTRL compared to OEP 
(0.22 ± 1.21 and 0.27 ± 1.45 vs 0.07 ± 0.33 and 0.05 ± 0.31, 
p = 0.042 for Lactobacillus; 0.54 ± 0.60 and 0.70 ± 0.76 vs 
0.77 ± 0.93 and 0.43 ± 0.38 for Ruminococcus, p = 0.0191, 
percentage relative abundance, V1 and V2, CTRL vs OEP, 
respectively). Also very small changes in relative abun-
dance of the less dominant bacterial genera were observed 
(0.0007 ± 0.002 and 0.0009 ± 0.001 vs 0.0011 ± 0.002 and 
0.0003 ± 0.0007, for an unknown genus Gemellaceae fam-
ily, p = 0.017; and 0.0011 ± 0.0026 and 0.0047 ± 0.0102 vs 
0.0015 ± 0.0031 and 0.0011 ± 0.0023, p = 0.032 for Anaero‑
fustis, percentage relative abundance, V1 and V2, CTRL vs 
OEP, respectively). Figure 3a shows the change in relative 
abundance at genus level for Bifidobacterium, Ruminococcus 
and Lactobacillus for OEP and CTRL treatments between 
V1 and V2.
Culture‑independent targeted quantitative enumeration 
of faecal bacteria
No significant differences were observed between 
treatment OEP and CTRL compared to baseline val-
ues (1.85 ± 2.89 and 2.17 ± 3.33 vs 1.39 ± 1.70 and 
2.20 ± 3.88) for Bifidobacterium spp. (1.07 ± 1.57 
and 1.06 ± 1.31 vs 0.53 ± 0.78 and 0.61 ± 1.11) for 
Lactobacillus/Enterococcus spp. (0.58 ± 0.97 and 
0.54 ± 0.54 vs 0.50 ± 0.79 and 0.59 ± 0.87, for Rumino‑
coccus obeum group V1 and V2, OEP vs CTRL, respec-
tively, p > 0.05 factorial ANOVA). Figure 4 shows the % of 
bacteria enumerated with oligonucleotidic probes specific 
for Bifidobacterium spp., Lactobacillus/Enterococcus spp. 
and Ruminococcus spp.
Fig. 2  Alpha- (a) and beta-
diversity (b) indexes after 16S 
rRNA metagenomic analysis of 
faecal samples collected before 
(T0) and after (T1) dietary 
intervention. Center lines show 
the medians; box limits indicate 
the 25th and 75th percentiles 
as determined by R software; 
whiskers extend 15 times the 
interquartile range from the 
25th and 75th percentiles; outli-
ers are represented by dots
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Quantitative PCR
No significant changes in faecal bifidobacteria (6.34 ± 0.95 
and 6.62 ± 0.92 vs 6.67 ± 0.74 and 6.72 ± 0.74, V1 and 
V2, P vs W, respectively, p > 0.05, factorial ANOVA) or 
in total faecal bacteria (10.08 ± 0.04 and 10.08 ± 0.05 vs 
10.07 ± 0.05 and 10.07 ± 0.04, V1 and V2, OEP vs CTRL, 
respectively, p > 0.05, factorial ANOVA) were observed 
after qPCR analysis (data not shown).
Urinary metabolites quantified by LC–MS
The results of targeted urinary polyphenols are shown in 
Table 3. Metabolites which were below the detection limit 
in the majority of samples were excluded from further 
analysis. Statistical analysis (factorial ANOVA) showed 
that a number of polyphenol metabolites were signifi-
cantly higher after OEP treatment compared to CTRL. In 
particular, 3-3-hydroxyphenyl propanoic acid (p = 0.009), 
3,4-dihydroxyphenyl acetic acid (p < 0.001), hippuric 
acid (p = 0.014), caffeic acid (p = 0.003), homovanillic 
acid (p < 0.001), 3-hydroxyphenyl acetic acid (p = 0.001), 
sinapic acid (p = 0.002), scopoletin (p = 0.001). 2,4-Dihy-
droxybenzoic acid (p < 0.001), 2,5-dihydroxybenzoic acid 
(p = 0.022), 3-(3-hydroxyphenyl) propionic acid (p = 0.009), 
were increased after OEP feeding.
Plasma metabolites quantified by LC–MS
The results of targeted quantification of plasma metabo-
lites by LC–MS are shown in Table 4. Metabolites which 
were below the detection limit in the majority of samples 
Fig. 3  Percentage relative abundance after 16S rRNA metagenomics analysis of dominant bacterial phyla in faecal samples collected before 
(T0) and after (T1) dietary intervention with olive-enriched product (OEP) or control product (Ctrl)
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were excluded from further analysis. Statistical analysis 
(factorial ANOVA) showed that 3,4-dihydroxyphenyl 
acetic acid (p = 0.002) and homovanillic acid (p = 0.003) 
were significantly higher after OEP treatment compared 
to CTRL. Most of the polyphenol metabolites were 
present at very low concentrations in plasma compared 
to urine since the plasma samples were taken in a fasted 
state.
Fig. 4  Difference in percentage 
relative abundance of relevant 
bacterial genera before (T0) and 
after (T1) dietary intervention 
with olive-enriched product 
(OEP) or control product 
(Ctrl). p = 0.73, p = 0.034 
and p = 0.02, respectively, for 
Bifidobacterium, Lactobacillus 
and Ruminococcus genera, after 
comparison of the difference 
T1–T0 between olive-enriched 
product (OEP) and control 
product (Ctrl), according to 
Mann–Whitney U test. Center 
lines show the medians; box 
limits indicate the 25th and 75th 
percentiles as determined by R 
software; whiskers extend 1.5 
times the interquartile range 
from the 25th and 75th percen-
tiles; outliers are represented 
by dots
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Table 3  Urinary polyphenol concentration (µM) quantified by mass 
spectrometry and normalized according to 24-h urine volume
Treatment time OEP Ctrl p value
T0 T1 T0 T1
Anthranilic acid (µM)
 Mean 1.30 1.38 1.33 1.46 0.467
 SD 0.98 0.94 0.86 1.39
4-Aminobenzoic acid (µM)
 Mean 0.03 0.02 0.03 0.03 0.173
 SD 0.02 0.01 0.01 0.02
Vanillin (µM)
 Mean 30.63 12.35 38.98 27.56 0.071
 SD 66.66 21.52 66.17 60.26
Acetovanillone (µM)
 Mean 2.66 2.58 3.13 2.60 0.435
 SD 2.45 1.47 3.64 1.87
2,4-DiOH-benzoic acid (µM)
 Mean 0.81 1.09 0.92 0.83 < 0.001
 SD 0.34 0.44 0.40 0.36
3,5-DiOH-benzoic acid (µM)
 Mean 3.01 2.25 3.65 3.11 0.483
 SD 1.93 1.64 3.32 2.86
2,5-DiOH-benzoic acid (µM)
 Mean 2.93 3.26 2.53 2.26 0.022
 SD 2.83 2.29 1.28 1.74
Neochlorogenic acid (µM)
 Mean 0.43 0.35 0.32 0.35 0.149
 SD 0.43 0.31 0.22 0.25
Chlorogenic acid (µM)
 Mean 0.59 0.57 0.55 0.46 0.738
 SD 0.44 0.51 0.51 0.41
Fertaric acid (µM)
 Mean 0.12 0.11 0.11 0.13 0.475
 SD 0.23 0.12 0.14 0.18
t-Coutaric acid (µM)
 Mean 0.04 0.03 0.05 0.05
 SD 0.07 0.04 0.08 0.11 0.614
Phloretin (µM)
 Mean 0.04 0.02 0.05 0.03
 SD 0.07 0.02 0.09 0.06 0.214
Phlorizin (µM)
 Mean 0.10 0.05 0.09 0.07
 SD 0.16 0.07 0.21 0.11 0.368
Naringenin (µM)
 Mean 0.07 0.04 0.10 0.08
 SD 0.08 0.03 0.11 0.10 0.709
Phloroglucinol (µM)
 Mean 15.09 15.43 15.68 15.54
 SD 5.49 5.93 6.26 6.26 0.788
4-Hydroxybenzoic acid (µM)
 Mean 6.27 6.17 6.81 5.24
 SD 3.87 4.13 3.06 2.24 0.076
Table 3  (continued)
Treatment time OEP Ctrl p value
T0 T1 T0 T1
m-Coumaric acid (µM)
 Mean 0.67 0.81 0.68 0.60
 SD 0.87 0.79 0.87 0.66 0.341
3-(3-Hydroxyphenyl) propanoic acid (µM)
 Mean 20.65 34.02 16.12 13.83
 SD 18.12 24.58 21.20 18.33 0.009
Vanillic acid (µM)
 Mean 2.80 3.16 2.32 2.25
 SD 2.50 2.19 2.39 1.95 0.499
3,4-Dihydroxyphenyl acetic acid (µM)
 Mean 1.39 22.09 1.68 0.94
 SD 3.04 13.19 3.28 2.11 < 0.001
Hippuric acid (µM)
 Mean 746.62 917.46 789.12 734.80
 SD 277.46 331.38 321.79 313.13 0.014
Caffeic acid (µM)
 Mean 0.45 0.64 0.47 0.44
 SD 0.34 0.28 0.24 0.24 0.003
Homovanillic acid (µM)
 Mean 20.96 54.41 21.63 19.62
 SD 7.36 21.87 8.12 8.02 < 0.001
Isoferulic acid (µM)
 Mean 1.45 1.72 0.59 0.93
 SD 3.88 4.62 0.61 1.76 0.577
t-Ferulic acid (µM)
 Mean 2.47 2.35 1.71 3.07
 SD 2.62 2.40 1.17 6.01 0.901
Alpha-hydroxyhippuric acid (µM)
 Mean 0.06 0.05 0.04 0.05
 SD 0.07 0.05 0.05 0.06 0.829
Urolithin A (µM)
 Mean 0.26 0.23 0.49 0.36
 SD 0.40 0.58 1.11 0.86 0.623
3-Hydroxyphenyl acetic acid (µM)
 Mean 34.82 65.11 28.76 29.58
 SD 40.05 43.29 18.77 27.69 0.001
Hydroferulic acid (µM)
 Mean 3.95 5.47 4.87 3.82
 SD 5.20 5.21 5.19 3.71 0.106
Sinapic acid (µM)
 Mean 0.64 1.06 0.78 0.67
 SD 0.51 0.78 0.71 0.69 0.002
Protocatechuic acid (µM)
 Mean 0.55 0.75 0.54 0.50
 SD 0.59 0.39 0.32 0.28 0.001
Scopoletin (µM)
 Mean 0.14 0.29 0.11 0.13
 SD 0.14 0.16 0.12 0.15 0.001
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Clinical measures of CVD risk and inflammation
Subjects in either group, OEP or CTRL, were matched 
for age and sex. Little difference was observed in baseline 
clinical parameters between the groups before dietary inter-
vention. After 8 weeks of treatment with either biscuit, no 
significant change in CVD or inflammatory makers was 
observed (Table 2). There was a trend towards reduced oxi-
dized LDL cholesterol in the OEP-treated group, but this 
was not significant either with respect to time or compared 
to the control treatment.
Sex impacted on urinary metabolite profiles
Although sex did not appear to influence to response to OEP 
ingestion in urine or in plasma, differences were observed 
in the concentrations of small phenolic acids excreted by 
women compared to men after the OEP treatment. Higher 
amounts of 3,5-diOH-benzoic acid, t-coutaric acid, narin-
genin, 4-hydroxybenzoic acid, 4-hydroxyphenyl acetic acid 
were excreted by male subjects compared to female subjects 
after the OEP treatment (Table 5). Since the gut microbiota 
is intricately involved in the metabolism of complex poly-
phenolic compounds and especially in the production of 
small phenolic acids, we measured whether the gut microbi-
ota of male and female subjects differed after OEP ingestion. 
Statistically significant differences in the relative abundance 
of Akkermansia, Bifidobacterium, Bacteroides, Prevotella, 
Table 3  (continued)
Treatment time OEP Ctrl p value
T0 T1 T0 T1
Cryptochlorogenic acid (µM)
 Mean 0.15 0.14 0.12 0.14
 SD 0.20 0.15 0.15 0.19 0.880
Syringic acid (µM)
 Mean 0.48 0.64 0.62 0.59
 SD 0.27 0.49 0.50 0.47 0.083
4-Hydroxyphenyl acetic acid (µM)
 Mean 109.73 125.51 96.81 101.87
 SD 86.90 65.10 40.88 57.97 0.290
Data represent the mean and standard deviation (SD) at the beginning 
(T0) and at the end (T1) of dietary intervention with olive-enriched 
product (OEP) or control product (Ctrl), and the relative p value after 
factorial ANOVA with Bonferroni’s correction. Cinnamic acid, caf-
taric acid, cis-piceide, luteolin, hesperidin, catechin, epicatechin, pro-
cyanidin B1, procyanidin B2 + B4, procyanidin B3, quercetin-3-Rha, 
kaempferol-3-Glc, kaempferol-3-rutinoside, dihydrokaempferol, 
quercetin-3-glucuronide, kaempferol-3-glucuronide, arbutin, p-cou-
maric acid, o-coumaric acid, gallic acid, ellagic acid, pyrocatechol, 
urolithin B, epigallocatechin gallate, epicatechin gallate, quercetin-
3-Glc + quercetin-3-gal, isorhamnetin-3-Glc, rutin, salidroside are not 
shown, since the levels fell below limit of quantification
Table 4  Plasma polyphenol concentration (µM) quantified by mass 
spectrometry
Data represent the mean and standard deviation (SD) at the beginning 
(T0) and at the end (T1) of dietary intervention with olive-enriched 
product (OEP) or control product (Ctrl), and the relative p value after 
factorial ANOVA with Bonferroni’s correction
Chlorogenic acid, cis-piceide, quercetin-3-Rha, quercetin-3-glucuron-
ide, kaempferol-3-glucuronide, t-ferulic acid, ellagic acid, protocate-
Treatment time OEP Ctrl p value
T0 T1 T0 T1
Anthranilic acid (µM)
 Mean 0.013 0.018 0.016 0.016 0.709
 SD 0.012 0.023 0.015 0.015
Vanillin (µM)
 Mean 0.092 0.087 0.078 0.065 0.614
 SD 0.090 0.058 0.042 0.030
2,4-DiOH-benzoic acid (µM)
 Mean 0.006 0.008 0.007 0.005 0.891
 SD 0.009 0.011 0.013 0.008
Phlorizin (µM)
 Mean 0.006 0.009 0.005 0.021 0.974
 SD 0.008 0.028 0.007 0.080
Pyrogallol (µM)
 Mean 0.182 0.157 0.238 0.235 0.738
 SD 0.319 0.357 0.584 0.465
4-Hydroxybenzoic acid (µM)
 Mean 0.217 0.046 0.274 0.094 0.798
 SD 0.303 0.086 0.301 0.166
3-(3-Hydroxyphenyl propanoic acid (µM)
 Mean 1.449 1.614 2.286 1.735 0.551
 SD 0.784 1.292 3.646 1.098
Vanillic acid (µM)
 Mean 0.041 0.033 0.041 0.055 0.689
 SD 0.028 0.020 0.025 0.099
3,4-Dihydroxyphenyl acetic acid (µM)
 Mean 0.010 0.651 0.006 0.021 < 0.001
 SD 0.032 0.493 0.031 0.062
Hippuric acid (µM)
 Mean 11.200 14.524 13.034 14.003 0.355
 SD 7.438 9.166 10.503 11.230
Caffeic acid (µM)
 Mean 0.024 0.018 0.013 0.015 0.651
 SD 0.045 0.023 0.016 0.018
Homovanillic acid (µM)
 Mean 0.093 0.217 0.069 0.090 0.003
 SD 0.075 0.135 0.061 0.057
Syringic acid (µM)
 Mean 0.015 0.007 0.012 0.032 0.093
 SD 0.021 0.014 0.016 0.109
4-Hydroxyphenyl acetic acid (µM)
 Mean 2.327 1.449 1.140 1.232 0.525
 SD 5.450 1.521 1.131 1.209 0.709
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Rikenellaceae, Barnesiellaceae, and Enterobacteriaceae 
were observed between the faecal microbiota of men and 
women (Fig. 5). These differences were statistically signifi-
cant after correction for repeated measures (Mann–Whitney 
U test, 2*1 exact p value) (Fig. 6).
Discussion
The primary objective of this study was to measure the 
impact of an olive pomace-enriched product (OEP) on the 
composition and metabolic output of the human gut micro-
biota. Considering the accepted physiological relevance 
of olive polyphenols, their apparent ability to protect LDL 
cholesterol particles from oxidative damage, and the fact 
that the gut microbiota appears to be intimately related 
to their metabolism in vivo, we measured changes in key 
olive-derived polyphenols, including tyrosol and HT, and 
their derived catabolites using a quantitative LC–MS-based 
strategy. The OEP biscuits did not have a major impact 
on the composition of the gut microbiota, but did induce 
subtle changes in relative abundances of certain bacteria. 
Significant differences in relative abundance of Lactoba‑
cillus, Ruminococcus, Gemellaceae and Anaerofustis were 
observed between treatments using community level 16S 
rRNA profiling. More quantitative analysis using flow 
cytometry-coupled fluorescent in situ hybridization did not 
confirm statistically significance for bifidobacteria, lacto-
bacilli or the Ruminococcus obeum-like bacteria. However, 
a trend was apparent, consistent between 16S rRNA gene 
sequencing, the probe-based FISH and qPCR, showing a 
small increase in bifidobacteria.
In terms of metabolic output, LC–MS-based targeted 
metabolomics confirmed that ingestion of the OEP biscuits 
resulted in a significant increase in urinary excretion of small 
phenolic acids derived from the metabolism of olive poly-
phenols. These small phenolic acids derive from the com-
bined activities of human phase I and II biotransformation 
and the action of the gut microbiota. OEP ingestion resulted 
in a significant increase in excretion of homovanillic acid, 
3,4-dihydroxyphenyl acetic acid, scopoletin, protocatechuic 
acid, sinapic acid, 3-hydroxyphenyl acetic acid, isoferulic 
acid, caffeic acid, hippuric acid, 3,3-hydroxyphenyl acetic 
acid, 2,5-dihydroxybenzoic acid and 2,4-dihydroxybenzoic 
acid. Many of these compounds derive from the breakdown 
pathways of the tyrosol group enriched in olives and/or the 
hippuric acid pathway, a pathway common to many classes 
of polyphenols. Both involve steps mediated by the gut 
microbiota and these catabolites and similar small phenolic 
acids have been reported to be excreted following ingestion 
of olive or olive fractions in previous studies [20–22, 36, 
37]. Few studies have reported the profile of metabolites 
present in fasted blood samples after chronic ingestion of 
olive pomace. Here we found that ingestion of the OEP bis-
cuits for 8 weeks resulted in a significantly higher level of 
tyrosol metabolites, homovanillic acid and 3,4-dihydroxy-
phenyl acetic acid (DOPAC). Homovanillic acid increased 
more then twofold in the OEP-treated group and was also 
about double the concentration after the CTRL treatment. 
For DOPAC, OEP induced more than tenfold increase in 
fasted blood concentrations, and a similar difference in 
magnitude was observed compared to the control group. As 
well as being associated with the protection of LDL choles-
terol particles from oxidative damage, both homovanillic 
acid and DOPAC have been reported to transiently associate 
with LDL cholesterol particles in blood thereby mediating 
their antioxidative effect. While most studies report these 
molecules to be relatively rapidly cleared from the blood 
[38], our study is one of the very few to record high levels of 
these antioxidants in fasted blood samples, many hours after 
ingestion of the olive-enriched food. This is an important 
observation for the possible functional activities of the OEP 
biscuit since persistence of these tyrosol-derived metabolites 
chuic acid, cryptochlorogenic acid, quercetin-3-Glc + quercetin-3-gal, 
hydroxytyrosol and tyrosol are not shown, since the levels fell below 
limit of quantification
Table 4  (continued)
Table 5  Total urine polyphenols that appeared significantly different 
between male (M) and female (F) volunteers at the end of interven-
tion (T1) with olive-enriched product (OEP)
Table shows the p values after factorial ANOVA with Bonferroni’s 
correction. Data represent mean and standard deviation (SD) of uri-
nary concentrations (µM), after normalization according to 24-h urine 
volume




 Mean 2.89 1.80 0.007
 SD 1.44 1.65
t-Coutaric acid (µM)
 Mean 0.04 0.02 0.021
 SD 0.04 0.04
Naringenin (µM)
 Mean 0.05 0.03 0.015
 SD 0.03 0.03
4-Hydroxybenzoic acid (µM)
 Mean 6.68 5.81 0.023
 SD 2.19 5.12
4-Hydroxyphenyl acetic acid (µM)
 Mean 153.66 105.41 0.036
 SD 80.96 42.55
77Eur J Nutr (2019) 58:63–81 
1 3
in blood, or indeed within the intestine, could prime antioxi-
dant defences and/or absorption of oxidized LDL cholesterol 
upon fat meal challenge. However, our current study was 
not designed to measure the effect of olive polyphenols on 
oxidized LDL cholesterol levels and therefore, any potential 
beneficial effect of the OEP biscuit awaits confirmation in 
an acute, postprandial study. Similarly, homovanillic acid 
and DOPAC are both involved in the dopamine pathway 
and have been shown to mediate other physiological effects 
including ameliorating age-related decline in muscle 
Fig. 5  Bacterial populations 
enumerated by FCM-FISH (% 
of total bacteria enumerated by 
SYBR green staining) in faecal 
samples collected before (T0) 
and after (T1) dietary interven-
tion with olive-enriched product 
(OEP) or control product (Ctrl). 
Center lines show the medians; 
box limits indicate the 25th and 
75th percentiles as determined 
by R software; whiskers extend 
1.5 times the interquartile range 
from the 25th and 75th percen-
tiles; outliers are represented 
by dots
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function [39] and brain function [40]. In addition, DOPAC 
has been shown to impact on the inflammatory response of 
immune cells to lipopolysaccharide or endotoxin, an inflam-
matory microbially derived signal associated with increased 
risk of metabolic disease [41]. However, any ability of the 
OEP biscuits to mediate such health effects awaits specifi-
cally and appropriately designed human studies.
In this current study, we also measured the ability of the 
OEP biscuit to modulate blood lipid profiles. Previous stud-
ies with whole plant foods or oat-derived beta-glucan in 
particular, have shown significant and clinically meaningful 
reductions in cholesterol upon ingestion [42]. However, the 
mechanisms by which these foods mediate their cholesterol 
lowering effects are still very much unclear, with different 
mechanisms suggesting involving phytosterols, gel-forming 
and cholesterol binding activities, modified bile acid profiles 
and/or prebiotic type modulation of the gut microbiota [43, 
44]. Our OEP, not containing the pit pulp of the olive, did 
not contain large amounts of plant phytosterols, and only 
had minor impact on microbiota composition. Although 
in this case, the olive pomace did not change blood lipid 
profiles, further studies, possibly with larger sample size 
be warranted, especially since the ability of olive and olive 
extracts in general to modulate blood lipid profiles remains 
to be convincingly established as per the EFSA statement on 
olive polyphenol extract health claims [18].
The quantities of small phenolic acids in urine differed 
between men and women upon OEP ingestion. Men excreted 
significantly more 3,5-diOH-benzoic acid, t-coutaric acid, 
naringenin, 4-hydroxybenzoic acid, 4-hydroxyphenyl acetic 
acid than women. A sex bias in polyphenol metabolism has 
been reported previously. Zamora-Ros et al. [45] analys-
ing the EPIC cohort study reported a significant sex bias 
in excretion of dietary polyphenols. Moreover, the sex dif-
ferences in dietary polyphenol metabolism also appears to 
be reflected in the concentration and profiles of polyphe-
nols or their derivatives in different tissues and organs, as 
shown for grape seed flavanols in rats [46]. Such sex effects 
could have important implications for the biological activity 
of these compounds, especially since a sex effect has also 
been reported in response to dietary interventions measuring 
physiological change and/or reduced risk of chronic disease 
Fig. 6  Significant differences between male (M) and female (F) in 
percentage relative abundance of bacterial genera after dietary inter-
vention with olive-enriched product (OEP), according to Mann–
Whitney U test. Center lines show the medians; box limits indicate 
the 25th and 75th percentiles as determined by R software; whiskers 
extend 15 times the interquartile range from the 25th and 75th per-
centiles; outliers are represented by dots
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upon intervention with polyphenol-rich foods [47]. The 
contribution of the intestinal microbiota to any sex-specific 
“metabotype” in terms of polyphenol metabolism remains 
very much unexplored. In our study, faecal samples collected 
from men and women post-OEP ingestion differed signifi-
cantly in the relative abundance of Akkermansia, Bifidobac‑
terium, Bacteroides, Prevotella, Rikenellaceae, Barnesiel-
laceae, and Enterobacteriaceae. Some of these bacteria are 
linked to host physiology and protection from metabolic and 
cardiovascular disease (Akkermansia and Bifidobacterium 
in particular), but also Bacteroides and Prevotella in rela-
tion to obesity and traditional dietary paradigms [48–50]. 
Similarly, the enterobacteria, which includes many intestinal 
pathogens, appear particularly susceptible to the antibacte-
rial activities of polyphenols [51]. The role of the human gut 
microbiota in determining the profile and quantities of dif-
ferent polyphenol breakdown products, their bioavailability, 
bioactivity and nutri-kinetics may constitute and important 
new compounding factor to be taken into consideration when 
designing human dietary interventions where polyphenols 
are considered mediators of physiological effect. Further 
data from similar human studies are required to confirm the 
involvement of the gut microbiota in gender-specific poly-
phenol metabolism and possible implications sex-specific 
response to diet.
In conclusion, ingestion olive pomace extract-enriched 
biscuits mediated small changes within the composition of 
the gut microbiota. Delivering 17.1 ± 4.01 mg/100 g HT 
and its derivatives, the OEP biscuits induced a significant 
increase in excretion of small phenolic acids in urine, indica-
tive of up-regulation of microbial polyphenol biotransfor-
mation in the intestine. Quantities of some small phenolic 
acids differed in urine of men and women, as did relative 
abundances of important members of the gut microbiota. 
OEP also led to a significant increase in homovanillic acid 
and DOPAC in fasted plasma samples, indicating related 
clearance of these compounds from the blood or extended 
release and uptake from the intestine. In either case, higher 
levels of these biologically active compounds mediated by 
OEP ingestion warrant further investigation in acute or post-
prandial studies specifically targeting LDL cholesterol oxi-
dation and cognitive function.
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